secwatch.observer — SEC 8-K summary
======================================

Issuer:     Rein Therapeutics, Inc. (RNTX)
CIK:        0001420565
Form:       8-K
Filed at:   2024-08-14T23:59:59+00:00
Accession:  0001193125-24-200739
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aileron Q2 2024 net loss $8.9M; positive Phase 1b data for LTI-03 in IPF
------------------------------------------------------------------------

- Net loss of $8.9M ($0.45 per share) vs $1.8M in Q2 2023; R&D expenses surged to $3.7M from $0.2M.
- Cash $21.9M as of June 30, 2024; raised $18.2M net from May 2024 registered direct offering.
- Cohort 1 of Phase 1b LTI-03 (2.5 mg BID) showed positive trends in 7 of 8 biomarkers with statistical significance in 3 fibrosis-related biomarkers.
- LTI-03 was generally well-tolerated; topline results from high-dose Cohort 2 expected in Q3 2024.
- Company expects cash to fund operations into second half of 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1420565/000119312524200739/0001193125-24-200739-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1420565/000119312524200739/d882513d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-200739

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer